• 3D structure of ONC201DiscoverX, a leader in GPCR profiling and screening services, recently highlighted imipridones, Oncoceutics’ proprietary class of small molecules, discussing their ability to target GPCRs, and the role that can play in developing cancer therapeutics.

    The article can be read here.

     

Photostream